JP2002500043A5 - - Google Patents

Info

Publication number

JP2002500043A5

JP2002500043A5 JP2000527646A JP2000527646A JP2002500043A5 JP 2002500043 A5 JP2002500043 A5 JP 2002500043A5 JP 2000527646 A JP2000527646 A JP 2000527646A JP 2000527646 A JP2000527646 A JP 2000527646A JP 2002500043 A5 JP2002500043 A5 JP 2002500043A5

Authority

JP

Japan

Prior art keywords

amino acid

polypeptide

deletion

isolated polypeptide

acid residues

Prior art date

1999-01-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 229920001184 polypeptide Polymers 0.000 description 105
• 102000004196 processed proteins & peptides Human genes 0.000 description 105
• 108090000765 processed proteins & peptides Proteins 0.000 description 105
• 238000012217 deletion Methods 0.000 description 44
• 230000037430 deletion Effects 0.000 description 44
• 125000003275 alpha amino acid group Chemical group 0.000 description 43
• 125000000539 amino acid group Chemical group 0.000 description 33
• 125000000729 N-terminal amino-acid group Chemical group 0.000 description 31
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 21
• 239000002773 nucleotide Substances 0.000 description 16
• 125000003729 nucleotide group Chemical group 0.000 description 16
• 102000039446 nucleic acids Human genes 0.000 description 11
• 108020004707 nucleic acids Proteins 0.000 description 11
• 150000007523 nucleic acids Chemical class 0.000 description 11
• 238000000034 method Methods 0.000 description 9
• 102000040430 polynucleotide Human genes 0.000 description 6
• 108091033319 polynucleotide Proteins 0.000 description 6
• 239000002157 polynucleotide Substances 0.000 description 6
• 238000004519 manufacturing process Methods 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 238000012258 culturing Methods 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 230000009826 neoplastic cell growth Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 241000024188 Andala Species 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1